Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study aims to examine whether estradiol is an appropriate for future Phase 3 studies as
second or third line endocrine treatment. In addition the protocol explores several
approaches to enhance the safety of estrogen therapy, including the establishment of the
efficacy of a lower dose than that currently recommended and through the early identification
of non-responders to avoid drug exposure in patients who are unlikely to benefit to estrogen
treatment.